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identified as a risk factor and also a prevalent condition for diabetic patients. Vita-
min D supplementation has been found to achieve appropriate glycemic control in
South Asian diabetic population. Due to mixed scientific evidence and lack of
guidelines, however, the extent of use of vitamin D in diabetic patients is under
studied. The objective of this studywas to understand the perceptions of vitaminD
supplements amongst adults with type 2 diabetes. METHODS: A literature review
was conducted to facilitate questionnaire designing. A separate version was cre-
ated for both the pharmacists and the physicians. These versions were differed to
reflect the scope of current Pharmacy and Medical practices in India. Being a pilot
study, a convenience sample of 10 physicians and 20 pharmacists was interviewed
from the suburban areas ofMumbai, India. Descriptive analyseswere performed to
compare the questionnaire responses. RESULTS: The relationship between vita-
min D deficiency and diabeteswas perceived to be positive in 70% of the physicians
and 75% of the pharmacists. The physicians perceived a pandemic of vitamin D
deficiency. Vitamin D supplements, however, were not commonly seen to be used
by diabetic patients. Amongst the users, the most common form of vitamin D
supplementwas in combinationwith calciumcarbonate. Use of fortified food items
with vitamin D and laboratory testing of serum D3 levels was also not popularly
done. CONCLUSIONS: In absence of pharmacy claims and utilization records, this
pilot study improves our understanding about the variability in the administration
of standard of care. Enhanced understanding of the perceptions and usage of nu-
tritional supplements like Vitamin D amongst many others can significantly im-
prove health outcomes in patients with Diabetes.
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OBJECTIVES: It is often unclear what the relative efficacies of available treatments
are due to lack of head-to-head clinical trial evidence. Indirect treatment compar-
ison (ITC) constitutes the standard method for comparing the relative efficacies of
treatments in the absence of head-to-head trial evidence. This study sought to
examine the difference in cost-effectiveness results between a series of decision
analyses compared to synthesising the clinical evidence with adjusted indirect
comparisons.METHODS: Cost-effectiveness analyses (CEA) of hypothetical Drug A
versus Drug B for three different scenarios were performed using a Markov model.
Three assumptions were made regarding the relative efficacies of these drugs: 1)
Drug A  Drug B; 2) Drug B 10% worse than Drug A and; 3) Drug B 20% worse than
Drug A. ITCs were undertaken for each scenario and the results were compared to
the results from the cost-effectiveness analysis. RESULTS: For Assumption 1, the
ITC showed a difference of up to 12%, whereas the CEA showed an almost perfect
overlay of the two scatterplots and the acceptability curves. In Assumption 2, the
ITC difference was up to 13%, while the scatterplots for the CEA were overlapping
and the acceptability curves clearly represented two different treatmentswith only
a small overlap at the upper range of the threshold. In Assumption 3, statistical
superiority of Drug A was demonstrated through the ITC, and the acceptability
curves of the CEA did not overlap. CONCLUSIONS: Themethodology introduced in
this paper is an alternative for decision makers to further examine the relative
effectiveness of two treatments when no head-to-head clinical trial data are avail-
able. A major limitation of this method is that detailed inputs (such as cost and
quality of life data) need to be readily available for the various treatments being
compared.
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OBJECTIVES: The Inverse Care Law, whereby health care services are less accessi-
ble to those in greater need, has been found to operate in a variety of health
systems. Tudor Hart asserted that market forces would exaggerate the maldistri-
bution of resources. The objective of this study is to examine whether the inverse
care law operates in a screening program for diabetic retinopathy (DR) in Hong
Kong (HK) with amixedmedical economy like other Asian countries.METHODS: A
randomized controlled trial has been conducted. All those with Type 1 or Type 2
diabetes from two public primary care clinics in Hong Kong were recruited and
then were randomly allocated into one group paying a fee of HK$60 (US$8) for
screening and the other group with free access. The outcomemeasures are uptake
of screening and extent of DR detected. RESULTS:After randomization, 1387 in free
and 1379 in pay groups were eligible for screening. 94.9%(1316/1387) and
92.6%(1277/1379)respectively agreed to participate in the study. The final screening
uptake rate were 88.5% (1165/1316)and 82.4% (1052/1277)respectively (P0.001).
Being in the pay group was associated with lower uptake of screening than in the
free group (OR0.59, 0.47-0.74) and lower prevalence of DR detected (20.3% VS
25.9%, P0.004). Subjects with higher socioeconomic status were more likely to
take up screening but with less DR detected. CONCLUSIONS: The inverse care law
appears to operate in a preventive intervention even with a relatively small co-
payment. There is a strong case for making effective preventive services free of
charge.
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OBJECTIVES: Evaluation and pricing mechanisms vary across countries for new
therapies. In Asia, South Korea has established a system based on cost-utility anal-
yses for pricing recommendations and subsequent negotiations. Japan, however,
uses a different pricing mechanism for new drugs that lack a comparator where a
premium could be applied to a breakeven price determined by a cost calculation
method. This study aims to compare the launch prices of drugs determined
through different pricing mechanisms. METHODS: Drugs listed and priced using
the cost calculation method in Japan from 2008 to 2011 were identified from the
MHLWwebsite. The same drugs and their published launch prices were identified
for South Korea. Using average annual exchange rates, South Korean prices were
converted to Japanese yen for comparison. Sensitivity analyses were conducted
using purchasing power parities for GDP. RESULTS: There were 54 new drugs
launched and priced using the cost calculation method in Japan. Among those, 24
(44%) were rewarded a premium from 10% to 40% with an average of 17.9%. Five
products were subject to a 5% price cut and the rest were priced at a breakeven
price. Only 16 (30%) of the 54 were identified for South Korea. In addition, for
products with several different dosage strengths available in Japan, only 1-2
strengths were reimbursed in South Korea. Each product listed in South Korea was
priced lower compared to its equivalent in Japan by 9% to 88% - or by 60% on
average. Results of a sensitivity analysis showed a wider variation in price differ-
ence with an average of 14% lower in South Korea. CONCLUSIONS: For products
priced using a cost calculation method in Japan, a more limited coverage with
lower listing prices was observed in South Korea. Further research is required to
study the impact of cost-utility analyses and pricing dynamics in the region.
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OBJECTIVES: To confirmwhether price premiums rewarded for new drugs in Japan
were justified by pharmacoecomic analysis. METHODS: We systematically re-
viewed the economic evaluation studies of new drugs launched in Japan between
April 2000 and March 2010 that were priced by the similar drug comparison
method, in which prices are set by comparison with prices of similar drugs. The
“Ichushi” and PubMed databases were used to search the published articles.
RESULTS: 220 drugs were priced by the similar drug comparison methods during
the 10-year period. In total, 22 published articles (16 drugs) were identified: 3 CUAs,
18 CEAs, and 1 CMA. In 10 out of 22 articles, only drug costs were included in the
cost estimation. There was a wide range of variation in outcomemeasures utilized
and life-years were only applied in 2 of 18 CEAs. The most common outcome used
was the proportion of patients who achieved target clinical results. Incremental
analysis was performed in 11 articles; however, the threshold for decision making
was mentioned in only 3 of these articles, even though 3 other studies did not take
into account because the results were dominant. While price premiums were re-
warded to all new drugs reviewed, only 8 of 16 drugs were cost-effective, 5 drugs
were not cost-effective, and the cost-effectiveness of 3 drugs was uncertain or
inconsistent between articles. CONCLUSIONS:Our literature review indicated only
halves of the drugs with premiums were reported to be cost-effective. However,
cost-effectiveness of the drugs could not be determined objectively because of a
wide range of variation in methods such as outcome measures and cost calcula-
tion. To utilize economic evaluations in policy making and clinical practice in
Japan, formulation ofmethodological standards is necessary to ensure consistency
among studies.
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OBJECTIVES: With the increasing demands for health care from rapid medical
technological advancement, the Taiwan National Health Insurance (TNHI) de-
mands for the development of systematic, transparent, and participatory pro-
cesses for selection of newhealth interventions to be included into theNHI Benefits
Schedule (NHIBS). Though evaluation of applications from the medical profession
for the listing of new health intervention on the NHIBS is recognized as a demo-
cratic decision making, its fairness and legitimacy have not been assessed. This
study aimed to assess the fairness and legitimacy of decisions in the priority setting
process for new health interventions into the NHIBS. METHODS: Both the four
conditions of accountability for reasonableness (Daniels and Sabin,2002):rele-
vance, publicity, appeals, and enforcement and the four steps of the trans-disci-
plinary model operational goals for priority setting in health care(Gibson et al,
2002):reasonableness, transparency, responsiveness, and accountability are used
to assess the fairness and legitimacy of the priority setting decisions. The data for
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analysis was from public documents, related audit reports, literature review, ob-
servations from the meetings of the NHI Benefits Negotiation responsible for rec-
ommending new technologies for the NHIBS and interviews with the meeting
participators. RESULTS: The Taiwan process for updating the NHIBS lacks the ap-
peals and enforcement conditions, and only partially follows the relevance and
publicity conditions. Only the reasonableness and transparency steps of the trans-
disciplinary model are partially fulfilled, but the priority setting process does not
satisfy responsiveness and accountability. CONCLUSIONS: The fairness and legit-
imacy of the priority-setting decision mechanism have not been established. The
lack of personnel engaged in health technology assessment and the desire for early
adoption of new technologies are an obstacle to achieving these conditions. Com-
prehensive changes in the priority-setting process should be made in order to
increase its acceptability among the different stakeholders.
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OBJECTIVES: To review the numbers of Phase III/IV clinical trials conducted in the
four Asian countries with the highest health care spending (China, Japan, Korea
and India), and the share of trials sponsored by the 12 multinational companies
(MNCs) with the highest revenues and profits, over the past 10 years. METHODS:
Searches were performed on ClinicalTrials.gov to identify industry-sponsored
Phase III/IV studies added in 2002, 2006 and 2011. The proportion of trials con-
ducted in China, Japan, Korea and India, and the percentages of trials sponsored by
12 MNCs (Pfizer, Johnson & Johnson, Merck, Abbott Laboratories, Eli Lilly, Bristol-
Myers Squibb, Amgen, Gilead Sciences, Mylan, Allergan, Biogen Idec and Gen-
zyme), were analysed. RESULTS: The total proportion of industry-sponsored Phase
III/IV trials in China, Japan, Korea and India increased over the time period studied
(5%, 17% and 22% in 2002, 2006 and 2011, respectively). In 2002 and 2006, the top 12
MNCs sponsored approximately one third of the Phase III/IV trials in the four coun-
tries. This figure, however, dropped to about 20% in 2011. Eight Phase III/IV studies
in 2011 were co-funded by one western manufacturer and an Asian firm. Notably,
no Asian partners were identified in the collaborative Phase III/IV trials in 2002 or
2006. CONCLUSIONS: The period of 2002-2011 saw an increase in the total number
of Phase III/IV trials conducted in the four Asianmarkets. However, the dominance
of the top MNCs in these markets seemed to be weakened during this period. Our
results also suggest that establishing partnerships with local companies might be
a key strategy for entering these major health care markets.
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OBJECTIVES: To compare the measurement precision and related properties be-
tween a short and generic instrument, 5-level EuroQoL Group’s 5-dimension (EQ-
5D-5L) questionnaire, and a longer and disease-specific measure Functional As-
sessment of Cancer Therapy – Breast (FACT-B) questionnaire in assessing breast
cancer patients. METHODS: This is an observational study of 269 Singaporean
breast cancer patients. To compare discriminative ability cross-sectionally and
longitudinally, the effect sizes (in standard deviation) of the EQ-5D-5L and the
FACT-B in relation to various health indicators were estimated. Test-retest reliabil-
ity was examined using the intraclass correlation (ICC) for patients with no change
in self-assessed performance status or quality of life. For each non-inferiority as-
sessment, a 90% confidence interval of the difference (FACT-B minus EQ-5D-5L) in
effect size or ICC was estimated and compared with a pre-defined non-inferiority
margin of 0.2. RESULTS: In a cross-sectional setting, the differences in the effect
size favored EQ-5D-5L and the 90% confidence intervals totally fell within the zone
that indicated the non-inferiority of the EQ-5D-5L (e.g. oncologist-assessed perfor-
mance status: –0.26 to 0.04; patient-assessed performance status: –0.48 to –0.16;
current evidence of disease: –0.28 to 0.08). In a longitudinal setting, the FACT-B
showed larger effect sizes and ICCs than the EQ-5D-5L. The confidence intervals,
however, overlapped the non-inferiority margin, thus non-inferiority in these two
aspects could not be confirmed. CONCLUSIONS: The EQ-5D-5L was non-inferior to
the FACT-B in discriminating breast cancer patients with different health condi-
tions cross-sectionally. Its longitudinal measurement properties need further in-
vestigations. Depending on the specific research aims of studies, the EQ-5D-5Lmay
serve as a reasonable alternative or supplementary instrument to the FACT-B in
assessing breast cancer patients’ health outcomes.
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OBJECTIVES: The Kidney Disease and Quality Of Life questionnaire (KDQOL-36) is a
shorter version of the Kidney Disease and Quality of Life-Short Form (KDQOL-SF), a
widely used health outcomes instrument for patients with chronic kidney dis-
eases. The aim of this study was to validate the KDQOL-36 in haemodialysis pa-
tients in Singapore. METHODS: Secondary KDQOL-SF (version 1.3) data collected
from a cross-sectional survey of haemodialysis patients attending the National
Kidney Foundation (NKF) dialysis centres from December 2006 to January 2007 in
Singapore was used. The KDQOL-SF items used to construct the KDQOL-36 scales
were analyzed to assess their psychometric properties. Internal consistency reli-
ability was assessed using Cronbach’s alpha. Criterion validity of the physical com-
ponent summary (PCS-12) and mental component summary (MCS-12) was as-
sessed by examining their correlation with the PCS-36 andMCS-36 calculated from
the KDQOL-SF. Item-to-scale correlation was examined and exploratory factor
analysis was performed to test the scaling assumptions of the KDQOL-36.
RESULTS: Totally 394 patients (male: 55.8%; mean age [SD]: 52.4 [11.7] years) com-
pleted the survey in English. Cronbach’s  value of the KDQOL-36 scales ranged
from 0.70 to 0.91. Correlation between the PCS-12 and PCS-36 was 0.75 and corre-
lation between MCS-12 and MCS-36 was 0.80. Correlation of items with their hy-
pothesized scales was higher than their correlation with other scales for all
KDQOL-36 items. Principle component factor analysis indicated a three-factor
structure for the generic items (variance accounted for: 63.8%) and a four-factor
structure for the disease-specific items (variance accounted for: 62.6%). The dis-
ease-specific scales and the PCS-12/MCS-12 were weakly to moderately correlated
(range of correlation: 0.28 to 0.41).CONCLUSIONS:TheKDQOL-36 appears a reliable
and valid measure of quality of life for haemodialysis patients in Singapore. More
research needs to be conducted to assess the construct validity of the instrument
using clinical data.
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OBJECTIVES: This study demonstrates how net benefit regression was used for
estimating censor adjusted cost-effectiveness of combination anti-HCV regimens
in an observational database study. METHODS: The Integrated Health Care Infor-
mation Services (IHCIS) National Managed Care Benchmark Database during Jan-
uary 1, 1997 to June 30, 2007, was used to identify study subjects with newly-
diagnosed HCV infection. First was to identify the primary effectiveness on time to
end-stage liver disease (ESLD) free survival and total direct cost during the follow-
up. Study perspective was the managed care organization with 2007 value of dol-
lars. Censored effectiveness and total cost of HCV care were adjusted with inverse
probability of weighting for the likelihood of being censored based on baseline
patient characteristics. The incremental net monetary benefit (INB) of antiviral
therapy (vs. no treatment) was estimated in the ordinary least square linear regres-
sion with adjustments for potential confounding. The INBs were tested with
White’s correction for heteroskedasticity. RESULTS: Patients at the time of HCV
diagnosed related cirrhosis, 48 weeks of initial combination antiviral regimens
(peg-interferon alpha and ribavirin) was cost-effective when the willingness-to-
pay value is $40,000 (INB, 4828, 95%, -14688-24345) but longer duration therapy
was not. Initial therapy appeared no difference in ESLD prevention for patients
with cirrhosis free, although the incidence of ESLD was low between treated and
no-treated patients. Cirrhosis presented strong impacts on treatment initiation.
Despite for cirrhosis and age, comorbid conditions had differential influence on
efficiency which were failed to take into account in prior modeling approach.
CONCLUSIONS: The propensity score adjusted net monetary benefit can be a valid
measure of cost-effectiveness in the practice setting with heterogeneous treat-
ment effects. Although prior modeling studies suggested that threshold value to
being cost-effectivewas lower in patientswithout cirrhosis, the results seemed not
hold after adjustments for the likelihood of starting treatment and unmeasured
bias.
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OBJECTIVES: Conventionally, generic quality of life health states, defined within
multi-attribute utility instruments, have been valued using a standard gamble or
time trade-off. Preference elicitation tasks for both are complicated, limiting the
number of health states each respondent can value, and therefore that can be
valued overall. Additionally, the two techniques have been shown to introduce bias
into health state valuation due to issues of (for example) discounting of future
events or risk preference. The objective of this research is to test an alternative
method for eliciting preferences for generic health states, and to produce an algo-
rithm for use in Australian cost-utility analyses.METHODS:We designed a DCE to
obtain values for SF-6D health states, and implemented it in an Australia-repre-
sentative online panel (n1,017). A range of specifications were estimated using a
random-effects probit model. Utility weights were then derived such that full
health and death were valued at 1 and 0 respectively. RESULTS: The results reflect
the broadly monotonic design of the SF-6D, and combination of levels to remove
illogical orderings did not lead to a poorer model fit. The most important dimen-
sions in the SF-6D were identified as physical functioning, pain, mental health and
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